<DOC>
	<DOCNO>NCT02091596</DOCNO>
	<brief_summary>This randomize , double-blind ( evaluator-blind ) , vehicle-controlled study 50 enrolled subject . Adult subject ( great 18 year old ) present mildly infect diabetic foot ulcer ( IDSA criterion ) full thickness ( i.e. , dermis involve joint capsule , tendon , bone ) . Subjects must also provide informed consent meet entry criterion enrol randomly assign receive PluroGel N PluroGel vehicle .</brief_summary>
	<brief_title>Topical PluroGel N Treatment Mildly Infected Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Nonhospitalized subject Type 1 Type 2 diabetes mellitus define American Diabetes Association diagnostic criterion ( ADA , 2010 ) . Diabetes may treat insulin , oral hypoglycemic agent , diet , combination therapy . Subjects whose diabetes consider `` control '' diet medication opinion physician . Males female least 18 year old . Subjects must consider investigator reliable , willing able give sign informed consent , must sign informed consent form . Subjects must full thickness ( i.e. , extend dermis involve tendon , bone , joint capsule ) ulcer foot distal malleoli surface area ≥1 cm2 wind undergone appropriate debridement . Subjects must localize mild infection ulcer , define IDSA criterion per Appendix C , PGN1300 Protocol , investigator believe would ordinarily treat outpatient basis . IDSA mild infection ulcer define : The presence ≥2 follow item : Local swell induration Erythema Local tenderness pain Local warmth Purulent discharge ( thick , opaque white sanguineous secretion ) Local infection involve skin subcutaneous tissue . If erythema , must &gt; 0.5 cm ≤2 cm around ulcer . Diabetic Foot InfectionGeneral Parameters Score least 2 must obtain order eligible enrollment . Diabetic Foot InfectionWound Size Score least 1 must obtain order eligible enrollment . The diagnosis mild infection must confirm immediately follow Day 0 ( Enrollment Visit ) debridement , although predebridement purulence count one manifestation infection . Subjects IDSAdefined moderate infection per Appendix C , include cellulitis extend &gt; 2 cm ; lymphangitis ; spread beneath fascia ; deep tissue abscess ; osteomyelitis ; gangrene ; muscle , joint , bone involvement . Subjects IDSAdefined severe infection per Appendix C , within PGN1300 Protocol include systemic toxicity metabolic instability ( e.g. , fever , chill , tachycardia , hypotension , confusion , vomit , leukocytosis , acidosis , hyperglycemia , azotemia ) . Subjects systemic inflammatory response sign , manifest ≥2 follow : Temperature &gt; 38°C &lt; 36°C Heart rate &gt; 90 beats/min Respiratory rate &gt; 20 breaths/min PaCO2 &lt; 32 mm Hg White blood cell count &gt; 12 000 &lt; 4000 cells/μL ≥10 % immature ( band ) form Subjects local wound complication ( e.g. , prosthetic material ) . Subjects currently receive antibiotic treatment localize infection study ulcer whose infection improve response treatment . Subjects require concurrent systemic antimicrobial study period infection , include diabetic foot ulcer . Subjects bone joint involvement suspect base clinical examination ( e.g. , bone note visually probe ) plain view Xray . Subjects clinically significant peripheral arterial disease require vascular reconstructive surgery . Subjects expect unable care ulcer hospitalization , vacation , disability , etc . study period , unable safely monitor infection status home . Subjects know active alcohol substance abuse within 6 month precede study entry . Subjects receive immunosuppressive agent ( corticosteroid ) , radiation therapy , cytotoxic agent . Subjects require treatment primary metastatic malignancy ( squamous basal cell carcinoma skin ) . Subjects systemically immunocompromising disease , acquire immune deficiency syndrome know human immunodeficiency virus infection . Subjects unexplained fever chill week prior enrollment . Subjects condition consider investigator reason disqualification may jeopardize subject safety interfere objectives trial ( e.g. , acute illness exacerbation chronic illness , lack motivation , history poor compliance ) . Subjects know allergy contraindication ingredient study product . Women breast feeding , pregnant , use contraception unless sterile . Subjects take expect take investigational therapy within 30 day prior entry enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Wound</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Infected</keyword>
	<keyword>Infection</keyword>
</DOC>